Scientists develop a method to optimize the delivery of mRNA to cells

Researchers have developed a simple but very effective method for delivering mRNA to target cells, opening up new possibilities for future non -vaccinated mRNA drugs for a wide range of diseases.

The study of Monash University, published in Nanotechnology of natureis a significant development in the way mRNA is precisely delivered to cells to maximize efficiency and minimize the off -target effects – vital components for future mRNA medications while they continue to evolve.

LED by the monash Institute of Pharmaceutical Scientists (MIPS), the Interdisciplinary Team of Resed Drafts Advanced Technologies Coupled with Preclinical Studies to Produce A Highly Versatile Method that Captures and antibodies to the surface of mrna-beladed lipid nanoparticles While the antibodies are inre their optimal orientation, Thus Enhancing the Mrna’s Effectiveness and Reducing Side Effects by Making Sure It Only Reaches Its Target Destination.

Lipid nanoparticles are tiny spherical lipid particles (fatty compounds) used to deliver drugs. They are an emerging technology for the delivery of genes and a key component of mRNA drugs because they help protect the cargo from the mRNA against decomposition or the body clearance before being able to reach the target cell.

Consequently, the MIPS method has increased mRNA binding to target cells 8 times compared to the methods of capturing conventional antibodies.

Co-Lead Author and MIPS Ph.D. The candidate Moore Zhe Chen said that with mRNA drugs, the delivery method is essential.

“In MRNA medicine, it is not only a question of what we deliver, it is a question of knowing where and how we deliver it. Our results show that the precise orientation of the targeting of ligands on lipid nanoparticles plays a vital role by ensuring that the mRNA reaches good cells with maximum effectiveness.

The expert in medication delivery and co-directing the author Author Auto Johnston, also MIPS, said that the efficient and precise delivery of mRNA is essential to advance mRNA medicines beyond their current use as vaccines.

“There is an increasing interest and an urgent need to develop specific, controlled and profitable systems to provide therapeutic mRNA,” said Associate Professor Johnston.

“In 2021, the world was introduced into the first vaccines of nanoparticles of arnm-lipid to fight against the COVVI-19 pandemic, demonstrating the fascinating potential of lipid nanoparticles to effectively provide mRNA to cells. However, current delivery techniques require a modification of antibodies, which can dilute their effectiveness and does not translate RNA not vaccine.

“In this study, we used powerful imaging techniques to develop a simple antibody capture system that does not require any change in antibodies and guarantees that antibodies are attached to lipid nanoparticles in an orientation that increases the connection to target cells. This is vital to develop new arnm drugs.

In addition, the team has confirmed the effectiveness of the method in preclinical studies, which have demonstrated the effective delivery of mRNA to T cells (white blood cells that play a vital role in the immune system) in mice, resulting in limited delivery outside the target to other immune cells.

Therapies based on emerging mRNA as a new powerful class of drugs for diseases that are difficult to deal with with conventional drugs. Beyond vaccines, current research focuses on the use of mRNA to target cancer and genetic disorders by allowing cells to produce therapeutic proteins exactly where they are necessary.

The MIPS team is now working to use this powerful platform to combat a range of difficult diseases. By allowing precise delivery of mRNA to specific cells of cells, technology is promising to advance treatment in cancer, genetic disorders and autoimmune diseases, where targeted therapies could considerably improve the results.